



U.S. Food and Drug Administration
Office of Regulatory Affairs
12420 Parklawn Dr.
Rockville, MD 20852
www.fda.gov

February 5, 2019

Dirk Tormans, Vice President Quality
Porton Pharma Solutions Ltd
Chongqing Chemical Industry Park, 1,
Changshou Chongqing, Chongqing, 401221 China

Dear Mr. Tormans, Vice President Quality:

The U.S. Food and Drug Administration (FDA) conducted an inspection at Porton Pharma Solutions Ltd, FEI 3006625990, located at Chongqing Chemical Industry Park, 1; Changshou, Chongqing, Chongqing, 401221 China, from 11/19/18 to 11/23/18. FDA has determined that the inspection classification of this facility is “voluntary action indicated” (“VAI”).¹ Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regards to current good manufacturing practice (CGMP).

A VAI inspection classification indicates that, although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time. Despite this facility inspection classification, FDA recommends that you address any observations noted on the Form FDA 483 issued at the conclusion of the inspection or otherwise conveyed to you following the inspection. If not corrected, the same or similar conditions could lead to a future inspection being classified as “official action indicated” (“OAI”).

This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.

An inspection classification of VAI for CGMP compliance will not directly negatively impact FDA’s assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by CDER’s Office of Pharmaceutical Quality. This letter does not address or reflect FDA’s decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is “closed” under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact Atul Agrawal via telephone at 240-402-4900 or email at atul.agrawal@fda.hhs.gov.

Sincerely,



Branch Chief
Foreign Pharmaceutical Quality Inspections

¹ See Inspection Classification Definitions, at <https://www.fda.gov/ICECI/Inspections/ucm223231.htm>.